Turn this role into an interview — a resume and cover letter built around what this employer wants.
Vrije Universiteit Brussel (VUB) is recruiting for a doctoral candidate embedded in the POLARIS consortium. You will generate and characterise GPRC5B-targeting nanobodies, undertake in vitro and in vivo analyses, and gain experience through planned secondments with POLARIS partner organisations. The project spans discovery to preclinical characterisation, with academic supervision by Prof.
Timo De Groof and Prof. Nick Devoogdt, and secondments at DPTX and Vrije Universiteit Amsterdam.
Biological sciences » Laboratory animal science
Medical sciences » Medicine
Organisation/Company Amsterdam UMC Research Field Biological sciences » Biology Biological sciences » Laboratory animal science Medical sciences » Medicine Researcher Profile First Stage Researcher (R1) Application Deadline 5 Oct 2026 - 21:59 (UTC) Country Netherlands Type of Contract Temporary Job Status Not Applicable Hours Per Week 36.0 Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No
Vrije Universiteit Brussel (VUB) is the recruiting organisation for this position. You will be employed by the Molecular Imaging and Therapy (MITH) research group and embedded in the POLARIS consortium. Your academic supervision will be provided by Prof. Timo De Groof and Prof. Nick Devoogdt.
This doctoral project focuses on developing GPRC5B-targeting nanobodies for use as research tools, diagnostic tracers and/or therapeutics. You will generate and characterise nanobodies using immune and synthetic nanobody libraries as well as AI-generated candidates.
The project will involve in vitro and in vivo characterisation of the generated nanobodies, including assessment of their affinity, specificity, modulatory effects, stability and biodistribution. Through the POLARIS network, you will also gain experience in AI-generated GPRC5B-targeting nanobodies and the functional characterisation of nanobodies in relation to GPRC5B signalling.
Planned secondments will provide hands‑on experience in the generation and validation of AI-generated GPRC5B-targeting nanobodies at DPTX and in the functional characterisation of the generated nanobodies at Vrije Universiteit Amsterdam.
Your academic embedding will be at the MITH research group, with the anticipated PhD defence at the Faculty of Medicine, Vrije Universiteit Brussel.
You will contribute to the development of GPRC5B-targeting nanobodies from initial discovery through to preclinical characterisation. Your work will include:
We are looking for a candidate with a Master's degree in life sciences, preferably molecular sciences. You bring:
Experience with animal experiments is an advantage. You should also be willing to travel for research activities and secondments at POLARIS partner organisations.
Fluency in spoken and written English is essential.
Eligibility criteria
Important, strict eligibility criteria according to MARIE SKLODOWSKA CURIE programs apply to applicants:
Additional comments
The application deadline is 5 October 2026. We aim to select the final candidate in October/November 2026.
Applicants may, where appropriate and in line with the recruitment procedure, also be considered for other POLARIS doctoral candidate positions that better match their profile and interests. You can highlight up to two additional POLARIS projects of interest in your application letter. This does not replace your application to the primary position, but helps the consortium identify potential alternative matches where relevant.
Would you like to know more about this PhD position? For substantive information about the vacancy, please contact dr Timo de Groof via timo.de.groof@vub.be.
Acquisition in response to this vacancy will not be considered.